Unique radionuclide therapy for the treatment of bone metastases in cancer patients is being introduced in Kazakhstan for the first time

The Medical Center Hospital of the President’s affairs Administration of the Republic of Kazakhstan will begin to use a unique method for the country to treat bone metastases of malignant neoplasms. This innovative therapy will be an important step in the development of oncological care, offering patients new opportunities to combat severe complications of cancer.

The method is based on the using the radiopharmaceutical drug “Samarium, 153Sm-Oxabifor”. This drug selectively accumulates in areas of bone damage, such as metastases or fractures, and irradiates them with β-particles without affecting healthy tissue. Due to its targeted focus, the method helps to effectively alleviate pain, reduce the need for painkillers, and slow the progression of the disease in bone tissue.

“The method’s uniqueness lies in its ability to significantly improve the quality of life of patients, minimizing the collateral damage and risks associated with traditional treatment methods. This is especially important for patients suffering from chronic pain and complications caused by metastases,” says the chief freelance specialist in nuclear medicine of the Ministry of Health, head of the Nuclear Medicine Center of the Medical Center Hospital of the President’s affairs Administration, Doctor of Medical Sciences Aigul Saduakassova.

To implement the new technology, an international master class will be held at the MCH from November 27 to 29. Leading nuclear medicine specialists from Kazakhstan and Russia will take part in the event. Among the invited experts are Vyacheslav Sukhov, head of the laboratory of isotope diagnostic and treatment methods at the FSBI “A.M. Nikiforov All-Russian Center for for Emergency and Radiation Medicine” (St. Petersburg), and Valery Krylov, head of the department of radiosurgery treatment with open radionuclides at the A. Tsyb Medical Radiological Research Center (Obninsk), recognized leaders in the field of radionuclide therapy. The doctors of the Hospital will also present their achievements in the development of nuclear medicine and share practical experience. Participation in the master class is free, and all participants will receive certificates. It is expected that the introduction of radionuclide therapy in Kazakhstan will open up access to modern cancer treatment technologies for patients, improve therapy results and strengthen the country’s position in the field of innovative medicine.